Literature DB >> 11407896

Nuclear translocation of lactosylated poly-L-lysine/cDNA complex in cystic fibrosis airway epithelial cells.

D T Klink1, S Chao, M C Glick, T F Scanlin.   

Abstract

Poly-l-lysine, with 40% of its amino groups substituted with lactose, is an effective vector to transfer the CFTR gene into CF airway epithelial cells and correct the chloride channel dysfunction. The intracellular fate of the lactosylated poly-l-lysine/cDNA complex was studied using confocal microscopy. In the presence of chloroquine the complex remained intact during internalization, intracellular transport, and, most importantly, transport into the nucleus. When cells were transfected in the presence of agents that enhance transfection efficiency such as E5CA peptide, a fusogenic peptide, or glycerol a similar fate of the lactosylated poly-l-lysine/cDNA complex was seen. However, when these agents were omitted from the transfection medium, the complex remained in the perinuclear region. Uncomplexed lactosylated poly-l-lysine reached the nucleus efficiently. In contrast mannosylated poly-l-lysine or unsubstituted poly-l-lysine complexed to plasmid did not. Therefore the nuclear accumulation of the complex may be attributed to the substitution of poly-l-lysine with lactose. It is hypothesized that the lactose residues provide for nuclear localization by means of targeting a potential lectin-like protein with galactose/lactose specificity. This mechanism may be responsible for the nuclear internalization of the complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407896     DOI: 10.1006/mthe.2001.0332

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 2.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

Review 3.  Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose.

Authors:  D T Klink; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 4.  Gene therapy of cystic fibrosis: the glycofection approach.

Authors:  I Fajac; P Briand; M Monsigny
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 5.  Functional peptides for siRNA delivery.

Authors:  Wanyi Tai; Xiaohu Gao
Journal:  Adv Drug Deliv Rev       Date:  2016-08-13       Impact factor: 15.470

Review 6.  Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus.

Authors:  Erik V Munsell; Nikki L Ross; Millicent O Sullivan
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

Authors:  Paul Zarogoulidis; Ekaterini Chatzaki; Konstantinos Porpodis; Kalliopi Domvri; Wolfgang Hohenforst-Schmidt; Eugene P Goldberg; Nikos Karamanos; Konstantinos Zarogoulidis
Journal:  Int J Nanomedicine       Date:  2012-03-22

Review 8.  Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

Authors:  Stefano Ferrari; Duncan M Geddes; Eric W F W Alton
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

Review 9.  Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor.

Authors:  Yao Xiao; Kun Shi; Ying Qu; Bingyang Chu; Zhiyong Qian
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-22       Impact factor: 6.698

Review 10.  Gene therapy progress and prospects: cystic fibrosis.

Authors:  U Griesenbach; S Ferrari; D M Geddes; E W F W Alton
Journal:  Gene Ther       Date:  2002-10       Impact factor: 5.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.